NCT04474327View on ClinicalTrials.gov

Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
Neonatal Sepsis
Interventions
DRUG

Montelukast Sodium

Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.

Trial Locations (1)

35116

Mansoura University Childran Hospital, Al Mansurah

All Listed Sponsors
lead

Mansoura University Children Hospital

OTHER

NCT04474327 - Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants | Biotech Hunter | Biotech Hunter